Latest news

• Another R&D flop for Incyte, but Jakafi keeps delivering

  Nevertheless, it’s another bit of bad news for Incyte after the epacadostat failure, what looks likely to be reduced royalties from Eli Lilly for rheumatoid arthritis JAK inhibitor Olumiant (baricitinib)

• AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

  be an under-estimate given that a third JAK inhibitor - Eli Lilly and Incyre’s Olumiant (baricitinib) - has been dogged by regulatory problems. ... Olumiant was finally approved by the FDA for RA a couple of weeks ago, but has been saddled with a black

• FDA panel undermines Lilly and Incyte’s baricitinib hopes

  Both doses of Lilly and Incyte’s drug are already approved in the EU, where it is sold as Olumiant, and the product brought in total revenues for Lilly of $46m

• AbbVie’s upadacitinib aces phase III trial

  The drug is vying to become the third drug in the class after Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib), which was turned down by the FDA at

• Lilly drops Hanmi-partnered arthritis drug

  Lilly’s willingness to take a risk on continuing development of the drug in other indications may be cut now that it has won approval for JAK inhibitor Olumiant (baricitinib) for